Last reviewed · How we verify
NCT04106778
DMT310-003 Topical in the Treatment of Acne Vulgaris
Phase 2 trial testing DMT310 in Acne Vulgaris in 181 participants. Completed in 4 May 2020.
4 May 2020
Quick facts
| Lead sponsor | Dermata Therapeutics |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 181 |
| Start date | 10 October 2019 |
| Primary completion | 4 May 2020 |
| Estimated completion | 4 May 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- DMT310 — full drug profile →
- Placebo
Conditions studied
- Acne Vulgaris — all drugs for Acne Vulgaris →
Sponsor
Dermata Therapeutics — full company profile →
Who can join
12 and older, any sex, with Acne Vulgaris. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04106778
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of DMT310
Trials testing the same drug.
- NCT06090721 — DMT310-009 Topical in the Treatment of Acne Vulgaris · Phase 3 · completed
- NCT03536637 — DMT310-001 Topical in the Treatment of Acne Vulgaris · Phase 2 · completed
Other recruiting trials for Acne Vulgaris
Currently open trials in the same condition.
- NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
- NCT07474883 — Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris · EARLY_PHASE1 · recruiting
- NCT07186413 — A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne · Phase 3 · recruiting
- NCT07056673 — Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris Study · NA · recruiting
- NCT07102186 — Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris · Phase 4 · recruiting
Other Dermata Therapeutics trials
Trials by the same sponsor.
- NCT06090721 — DMT310-009 Topical in the Treatment of Acne Vulgaris · Phase 3 · completed
- NCT03536637 — DMT310-001 Topical in the Treatment of Acne Vulgaris · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04106778 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dermata Therapeutics
- Last refreshed: 22 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04106778.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing